Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2013-10-25 Interim / Quarterly Rep…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB 9 month interim report NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Tussentijds verslag' (Interim Report) for UCB covering the first nine months of 2013. It contains detailed financial tables, revenue breakdowns by product and region, and management commentary on business performance and pipeline developments. It is not a short announcement (it is over 13,000 characters) and provides substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). 9M 2013
2013-10-25 Dutch
Cimzia® (certolizumab pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Regulatory Filings Classification · 95% confidence The document is a press release dated October 18, 2013, announcing the FDA approval of Cimzia® for active ankylosing spondylitis (AS). It contains detailed clinical trial data, safety warnings (including risks of serious infections, malignancies, and heart failure), and information about the disease itself. This structure—a formal announcement of a significant regulatory event (FDA approval) coupled with detailed safety information—is characteristic of an Earnings Release (ER) or a general press release announcing a major corporate/product milestone. Since it focuses on the immediate announcement of a regulatory outcome and key financial implications (peak sales forecast), it aligns best with the 'Earnings Release' category, which often encompasses major operational/regulatory news releases, even if not strictly quarterly earnings. It is not a full Annual Report (10-K), a transcript (CT), or a specific governance/shareholder document. Given the context of a major drug approval announcement, ER is the most appropriate fit among the provided options for a time-sensitive, high-impact corporate announcement.
2013-10-18 English
Cimzia® (certolizumab pegol) approuvé par la FDA dans le traitement des adultes atteints de spondylarthrite ankylosante active
Regulatory Filings Classification · 95% confidence The document is a press release dated October 18, 2013, announcing that Cimzia® (certolizumab pegol) has been approved by the FDA for treating active ankylosing spondylitis (AS) in adults. It details the clinical study results (Phase 3), safety profile, and context of other indications. This type of announcement, focusing on key results and regulatory milestones for a specific period or approval, aligns best with an Earnings Release (ER) or a general regulatory/corporate announcement. Since it is a detailed announcement of a major regulatory event (FDA approval) and includes financial context (€1.5 billion sales forecast), it is more specific than a general Regulatory Filing (RNS). However, it is not a comprehensive periodic report (like 10-K or IR) nor a transcript (CT) or a management discussion (MDA). Given the content is a major corporate news announcement regarding product approval and performance outlook, it functions similarly to an Earnings Release, which often includes key operational and regulatory updates, even if not strictly quarterly results. Since the core is a major corporate announcement about a product milestone, and it is not a formal periodic report, 'ER' is the closest fit for a significant, time-sensitive corporate update, although 'RNS' is a possibility if it were purely regulatory. Given the inclusion of sales forecasts and detailed clinical data summary, 'ER' is chosen as the primary classification for a major corporate news release.
2013-10-18 French
Cimzia® (certolizumab pegol ) door de Amerikaanse FDA goedgekeurd voor de behandeling van volwassenen met actieve ankylopoetica spondylitis
Legal Proceedings Report Classification · 99% confidence The document is a press release written in Dutch, dated October 18th, announcing that the US FDA has approved Cimzia® (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis (AS). It details the study results, safety information (including boxed warnings about infections and malignancies), and provides context on the drug's use in other regions (Europe). This format—a formal announcement of a significant regulatory event (FDA approval) accompanied by clinical and safety data—is characteristic of an Earnings Release (ER) or a general press release announcing a major corporate/product development. Since it focuses on the immediate announcement of a regulatory milestone and key financial implications (projected sales), 'ER' (Earnings Release) is the closest fit among the options for a major, time-sensitive corporate announcement, although 'RNS' (Regulatory Filings) is also plausible as a general announcement. Given the structure and the focus on a major product update/approval, ER is selected as the primary category for significant, time-bound corporate news releases, even if not strictly quarterly earnings.
2013-10-18 Dutch
Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Regulatory Filings Classification · 95% confidence The document is a press release dated September 30, 2013, announcing that Cimzia® (certolizumab pegol) has been approved by the U.S. FDA for the treatment of active psoriatic arthritis (PsA). It details the supporting clinical study (RAPID™-PsA), efficacy results (ACR20), safety profile, and compares this approval to existing indications (RA, Crohn's disease). The text also includes extensive 'IMPORTANT SAFETY INFORMATION' regarding serious infections, malignancies, and other risks associated with the drug. This structure—a news announcement detailing a regulatory milestone (FDA approval) and providing key clinical/safety data—is characteristic of an Earnings Release (ER) or a general press release related to product news. Since it is not a comprehensive periodic financial report (10-K or IR), nor a transcript (CT), nor a presentation (IP), and it focuses on a specific product development/regulatory event, it best fits the 'Earnings Release' category, which often encompasses major corporate news releases, even if not strictly tied to quarterly earnings figures. Given the focus on a major regulatory approval and associated clinical data, ER is the most appropriate fit among the options, as it functions as a major corporate announcement. However, upon reviewing the definitions, 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is about a drug approval, not financial results highlights. Since it is a formal announcement of a significant corporate/regulatory event, and it doesn't fit any other specific category (like M&A, Capital Change, or Dividend), the most suitable fallback category for a significant, non-standard regulatory/product announcement is 'Regulatory Filings' (RNS) or potentially 'Legal Proceedings Report' (LTR) if the focus was on litigation, but here it's an approval. Given the nature of the announcement (FDA approval), 'RNS' (General regulatory announcements and fallback category) is the most appropriate classification when a specific product/regulatory event category is missing.
2013-09-30 English
Cimzia® (certolizumab pegol) approuvé par la FDA dans le traitement des patients adultes atteints de rhumatisme psoriasique actif
Regulatory Filings Classification · 95% confidence The document is a press release dated September 30, 2013, announcing that Cimzia® (certolizumab pegol) has been approved by the FDA for the treatment of active psoriatic arthritis (PsA). It details the supporting clinical study (RAPID™-PsA), discusses the drug's efficacy and safety profile, and includes extensive Important Safety Information (ISI) regarding infections, malignancies, and other risks. This format—a formal announcement of a regulatory milestone (FDA approval) accompanied by clinical data summaries and mandatory safety warnings—is characteristic of an Earnings Release (ER) or a general press release announcing a significant corporate/product event. Since it is an initial announcement of a key result (FDA approval) rather than a comprehensive periodic financial report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate fit among the provided options for a major, time-sensitive corporate announcement, even though it is not strictly an earnings report. Given the context of a major drug approval announcement, it functions similarly to an ER in terms of immediate market impact and required disclosure.
2013-09-30 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.